American Society of Hematology

Figure 1.

EFS (2-year, 79.1%; 95% CI, 67.2-87.1) and OS (2-year, 97%; 95% CI, 88.1-99.2) for newly diagnosed patients with ALK+ ALCL in arm BV of ANHL12P1.

EFS (2-year, 79.1%; 95% CI, 67.2-87.1) and OS (2-year, 97%; 95% CI, 88.1-99.2) for newly diagnosed patients with ALK⁺ ALCL in arm BV of ANHL12P1.

This Feature Is Available To Subscribers Only

Sign In or Create an Account